All Small Molecules articles
-
NewsOral antiviral GHP-88310 candidate shown to block measles transmission in ferret model
An experimental oral antiviral has demonstrated the ability to prevent both airborne and contact-based transmission of a measles surrogate virus in ferrets, offering a potential new tool to complement vaccination during outbreaks.
-
NewsInsilico Medicine nominates ISM9528 non-opioid chronic pain candidate using AI
Insilico Medicine has nominated ISM9528, an orally available, brain-penetrant non-opioid candidate targeting a previously unrecognised pain mechanism, as its 31st AI-generated preclinical compound since 2021, with efficacy exceeding morphine in some preclinical models.
-
NewsNew drug SB-0110 targets levodopa’s two biggest clinical limitations for Parkinson’s
A computational biology-derived compound has shown promise in preclinical models by simultaneously improving levodopa response and reducing dyskinesia — two of the most significant challenges in long-term Parkinson’s disease management.
-
NewsNTX-301 targets treatment-resistant AML via Hippo pathway in preclinical study
A novel epigenetic therapy has demonstrated activity against treatment-resistant acute myeloid leukaemia in preclinical models, including high-risk TP53-mutant disease, by selectively reactivating the Hippo tumour-suppressor pathway.
-
NewsNew BET therapies could help beat resistance in solid cancers
A new review finds that next-generation BET-targeted therapies, including selective inhibitors and PROTACs, are addressing the clinical shortcomings of earlier compounds and reviving interest in this approach for solid tumour treatment.
-
NewsAUTAC strategy targets MCL1 to overcome myeloma treatment resistance
Scientists at VCU Massey Comprehensive Cancer Center have developed an autophagy-targeting chimera that redirects cancer cells’ own recycling machinery to degrade the survival protein MCL1, offering a potential new strategy to overcome treatment resistance in multiple myeloma.
-
NewsNew BET inhibitors could overcome barriers in solid tumour treatment
A new review examines how advances in drug design, PROTAC degraders and combination therapies are reviving the clinical prospects of BET inhibition in solid tumours, after early-generation compounds were hampered by toxicity, resistance and modest efficacy.
-
NewsKCL-286 targets multiple Alzheimer’s pathways in preclinical study
A repurposed small molecule originally developed for spinal cord injury has demonstrated the ability to address multiple disease-relevant pathways in Alzheimer’s disease, including DNA damage and neuroinflammation, offering a potential route to disease-modifying therapy.
-
NewsInsilico Medicine launches Phase III trial of AI-designed Rentosertib drug
Insilico Medicine has advanced its AI-discovered TNIK inhibitor Rentosertib into a 320-patient Phase III trial for idiopathic pulmonary fibrosis, marking a landmark moment for generative AI drug discovery.
-
NewsAI and lab techniques accelerate tuberculosis drug discovery
Researchers at UMass Amherst have combined high-throughput laboratory screening with an AI neural network to identify compounds capable of breaching the protective outer membrane of Mycobacterium tuberculosis, potentially accelerating the search for new TB therapeutics.
-
NewsXL20 drug candidate shields motor neurons from ALS-linked TDP-43 damage
A newly identified experimental compound, XL20, has demonstrated neuroprotective effects in mouse models and human motor neurons by targeting a conserved disease-linked region of TDP-43, a protein central to ALS pathology.
-
NewsHidden vulnerability in persister cells could prevent KRAS cancer relapse
Scientists at Chiba University have identified a metabolic vulnerability in drug-tolerant cancer cells that survive KRAS-targeted therapy, opening a potential route to combination treatments designed to prevent disease recurrence in lung, pancreatic and colorectal cancers.
-
NewsLargest chemical reactions database launched to boost AI drug discovery
Researchers at the University of Michigan have assembled a database of more than 50,000 chemical experiments, offering AI systems an unprecedented resource to accelerate drug discovery and reduce reliance on scarce precious metal catalysts.
-
NewsGinkgo Bioworks launches ADME-One platform for early-stage screening
Ginkgo Bioworks has launched ADME-One, an integrated platform combining high-throughput ADME testing with AI-powered human pharmacokinetic projections.
-
NewsNew malaria drug T111 targets all parasite stages in single treatment
A novel compound developed over 15 years of research has demonstrated unprecedented activity against liver, blood and sexual stages of Plasmodium parasites, possibly positioning it as a potential cure for malaria.
-
NewsSafer diazo compound synthesis advances medicinal chemistry capabilities
Researchers at Tokyo University of Science have developed a safer synthetic route to β-heteroatom-substituted diazo esters, eliminating the need for toxic diazomethane. The azide-to-diazo conversion method uses mild conditions and readily available starting materials, potentially streamlining early-stage drug discovery and compound library synthesis.
-
ArticleWhen scale meets insight: reinventing SPR for the future of drug discovery
Carterra’s new 48-channel SPR platform reimagines throughput, automation and data quality for modern discovery workflows.
-
NewsNew method streamlines C–N bond formation for amine synthesis
Researchers at the University of Wisconsin–Madison have reported a new approach to forming carbon–nitrogen bonds, a critical step in the synthesis of amines widely used in pharmaceuticals, agrochemicals and polymers.
-
NewsCombining antibodies with natural compounds may improve Alzheimer’s treatment
Researchers at the University of Waterloo have demonstrated that combining anti-amyloid antibodies with naturally derived small molecules, such as resveratrol and curcumin, may improve therapeutic outcomes in Alzheimer’s disease.
-
NewsInsilico announces ISM6200 AI-designed drug candidate for ovarian cancer and cortisol disorders
Insilico Medicine has nominated ISM6200, a preclinical drug candidate designed using generative AI to target NR3C1, a receptor involved in cortisol regulation.